Quantcast
 
Read Larry Connors' blogShort Term Trading Strategies


CGEN

Compugen Reports Discovery of Genetic Biomarker for Predisposition to Type 2 Diabetes - 11/11 - 01:00 AM ET

Compugen finds biomarker for predisposition to diabetes: Predisposition markers are of particular value in diseases like type 2 diabetes, where lifestyle and health factors are known to play an important role - 11/09 - 03:44 PM ET

SmallCapReview.com: Small Cap Stocks to Watch - CGEN, CMED, CYTK - 11/09 - 09:34 AM ET

Compugen signs new research and licensing agreement for biomarker candidate - 11/09 - 08:52 AM ET

Compugen Announces Discovery of Genetic Biomarker for Predisposition to Type 2 Diabetes - 11/09 - 07:00 AM ET

Compugen Announces Preeclampsia Biomarker Collaboration - 11/05 - 07:00 AM ET

Top IT Support Services Recognition for Compugen - 10/28 - 03:00 PM ET

Compugen loss narrows: The lower loss reflected the sale of Evogene shares. - 10/27 - 04:35 PM ET

Compugen Reports Third Quarter 2009 Financial Results - 10/27 - 07:00 AM ET

Compugen Presents DAC Blockers Platform and Initial Product Candidates at Fifth Peptide Engineering Meeting in Barcelona, Spain - 10/26 - 07:00 AM ET

Compugen Ltd. to Review Third Quarter 2009 Results on Tuesday, October 27, 2009 - 10/20 - 07:00 AM ET

Compugen and Bayer Schering Pharma Ink Collaboration Pact - 10/19 - 11:42 PM ET

Compugen and Bayer Schering to collaborate on oncology target and splice variants - 10/16 - 02:40 PM ET

Compugen signs collaboration agreement with Bayer: The company's share jumped on the news. - 10/14 - 03:45 PM ET

Compugen and Bayer Schering Pharma form research collaboration - 10/14 - 05:03 AM ET

Compugen and Bayer Schering Pharma to Collaborate on Compugen Discovered Oncology Target and Splice Variants - 10/13 - 07:00 AM ET

Compugen Named First Canadian Microsoft(R) Authorized Refurbisher - 10/01 - 09:01 AM ET

Compugen Honoured for Long-Term Contribution to Canadian Literacy - 09/24 - 09:01 AM ET

Microsoft Case Study Features Compugen, a Global Leader in Deployment of Microsoft Technologies - 09/22 - 12:00 PM ET

Microsoft Case Study Features Compugen, a Global Leader in Deployment of Microsoft Technologies - 09/22 - 12:00 PM ET

Page 1 of 4     1  2   3   4      Previous  |  Next

<< Back to Stock Index

 

Most Popular News
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.